ZEAL
NASDAQZealand Pharma A/S
News · 26 weeks35-18%
2025-12-142026-06-07
Mix2590d
- Other21(84%)
- Earnings2(8%)
- Dividends1(4%)
- Leadership1(4%)
Latest news
25 items- PRZealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysisCompany announcement No. 21 / 2026 Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP-1 dual agonist, from baseline.1 Detailed pre-specified analysis from a sub study of SYNCHRONIZE-1 show that, relative to baseline, survodutide achieved a reduction of up to 34% in visceral fat, with
- PRNew data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management experience for people living with overweight and obesityPress release – No. 13 / 2026 New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management experience for people living with overweight and obesity Clinically meaningful, double-digit weight loss demonstrated through week 42 Placebo-like tolerability observed and low rates of treatment discontinuation due to gastrointestinal adverse events Treatment associated with improvements in cardiometabolic disease risk factors, including reductions in waist circumference, high-sensitivity C-reactive protein and triglycerides Data reinforces the potential of petrelintide to enhance t
- PRZealand Pharma to participate in the Goldman Sachs Global Healthcare ConferencePress release – No. 12 / 2026 Zealand Pharma to participate in the Goldman Sachs Global Healthcare Conference Copenhagen, Denmark, June 2, 2026 - Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, announced that Chief Executive Officer, Adam Steensberg, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on Tuesday, June 9, 2026, at 1:20pm EDT (7:20pm CEST). A live audio webcast of the fireside chat will be available at https://event.webcasts.com/starthere.jsp?ei=1764316&tp_key=1b9fe8174a&language=en-us, and accessible through the company's website at https://www.z
- PRZealand Pharma - Transactions related to share buy-back program (week 22, 2026)Company announcement No. 20 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 22, 2026) Copenhagen, Denmark, June 1, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the "Program") for week 22 (May 26-29, 2026). The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, "MAR") and Commission Delegated Regulation (EU) 2016/1052 (the "Safe Harbour Regulation"). Reference is made to company announcement no. 15 / 2026 dated May 7,
- PRTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsCompany announcement – No. 19 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, May 29, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, has received information on transactions in Zealand Pharma's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions. Please see the attached file(s). About Zealand Pharma Zeala
- PRZealand Pharma to participate in the Jefferies Global Healthcare ConferencePress release – No. 11 / 2026 Zealand Pharma to participate in the Jefferies Global Healthcare Conference Copenhagen, Denmark, May 27, 2026 - Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, announced that Chief Financial Officer, Henriette Wennicke, and Chief Scientific Officer, Utpal Singh, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026, at 12:45pm EDT (7:45pm CEST). A live audio webcast of the fireside chat will be available at https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/guest_book?session_id=neMJD52ZimWD5Fa274J7iC, and accessib
- PRZealand Pharma to Present Data at the American Diabetes Association's 2026 Scientific SessionsPress release – No. 10 / 2026 Zealand Pharma to Present Data atthe American Diabetes Association's 2026 Scientific Sessions Late-breaking Phase 2 ZUPREME-1 data on petrelintide to be featured as ePoster Theater presentation and poster sessions Copenhagen, Denmark, May 27, 2026 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that data from its obesity and metabolic health pipeline will be presented at the 2026 Scientific Sessions of the American Diabetes Association® (ADA) taking place June 5–8, 2026, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. "The ADA's Scientific Session
- PRZealand Pharma - Transactions related to share buy-back program (week 21, 2026)Company announcement No. 18 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 21, 2026) Copenhagen, Denmark, May 26, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the "Program") for week 21 (May 18-22, 2026). The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, "MAR") and Commission Delegated Regulation (EU) 2016/1052 (the "Safe Harbour Regulation"). Reference is made to company announcement no. 15 / 2026 dated May 7,
- PRResolutions from Zealand Pharma's Extraordinary General Meeting 2026Company announcement – No. 17 / 2026 Resolutions from Zealand Pharma's Extraordinary General Meeting 2026 Copenhagen, Denmark, May 26, 2026 - Zealand Pharma A/S ("Zealand Pharma" or the "Company") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today held an Extraordinary General Meeting. At the Extraordinary General Meeting, all proposals presented to the Extraordinary General Meeting were approved. Resolutions considered at the Extraordinary General Meeting: Board elections The following new candidate was elected to the Board of Directors as recommended by Zealand Pharma's Nomination Committee: Camilla Sylvest No other changes
- PRZealand Pharma - Transactions related to share buy-back program (weeks 19-20, 2026)Company announcement No. 16 / 2026 Zealand Pharma - Transactions related to share buy-back program (weeks 19-20, 2026) Copenhagen, Denmark, May 14, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the "Program") for week 19 (May 7-8, 2026) and week 20 (May 11-13, 2026). The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, "MAR") and Commission Delegated Regulation (EU) 2016/1052 (the "Safe Harbour Regulation"). Reference is made to company announc
- PRZealand Pharma - Execution framework for share buy-back programCompany announcement No. 15 / 2026 Zealand Pharma - Execution framework for share buy-back program Copenhagen, Denmark, May 7, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that it has decided to initiate a share buy-back program (the "Program") in accordance with company announcement no. 13 / 2026. This regulatory update summarizes the execution framework of the Program, to which the following terms apply: The Program will be implemented in accordance with Regulation (EU) No 596/2014 (the Market Abuse Regulation, "MAR") and Commission Delegated Regulation
- PRZealand Pharma Announces Financial Results for the First Three Months of 2026Company announcement – No. 14 / 2026 Zealand Pharma Announces Financial Results for the First Three Months of 2026 A defining start to 2026, marked by pivotal progress for leading obesity assets, petrelintide and survodutide, and strong momentum in driving the next wave of metabolic health innovation. Announced decision to advance petrelintide into Phase 3 trials in H2 2026 following positive topline results from the Phase 2 ZUPREME-1 trial, demonstrating double-digit weight loss with a placebo-like tolerability, supporting its potential to redefine the weight management experience for people living with obesity or overweight. Announced Boehringer Ingelheim's positive topline results fro
- PRZealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back programCompany announcement No. 13 / 2026 Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program Robust cash position of USD 2.3 billion (DKK 14.5 billion) as of March 31, 2026Financial strength to be further enhanced by significant milestone payments of USD 700 million from Roche in 2026Continuing to invest significantly in research capabilities to build a leading metabolic health pipeline and execute on Metabolic Frontier 2030 strategy Copenhagen, Denmark, May 7, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces that it has decided to ini
- PRThe Zealand Pharma Board of Directors proposes to elect Camilla Sylvest to the Board of Directors at an upcoming Extraordinary General MeetingPress release - No. 9 / 2026 The Zealand Pharma Board of Directors proposes to elect Camilla Sylvest to the Board of Directors at an upcoming Extraordinary General Meeting Camilla Sylvest will bring deep commercial expertise to the Board at a critical stage, as Zealand Pharma advances towards establishing its commercial footprint The final decision to elect Camilla Sylvest is still subject to shareholder approval at an upcoming Extraordinary General Meeting Copenhagen, Denmark, May 1, 2026 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that its Board of Directors proposes to elect Camilla Sylvest
- PRZealand Pharma convenes Extraordinary General Meeting on May 26, 2026Company announcement – No. 12 / 2026 Zealand Pharma convenes Extraordinary General Meeting on May 26, 2026 Copenhagen, Denmark, May 1, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, hereby convenes an Extraordinary General Meeting. The Board of Directors of the Company hereby convenes an Extraordinary General Meeting (the "General Meeting") of the Company to be held on: Tuesday, May 26, 2026, at 1:00 pm (CEST) The General Meeting will be held as a physical meeting at Plesner Advokatpartnerselskab, Amerika Plads 37, 2100 Copenhagen Ø, Denmark. No live webcast or recordi
- PRZealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial resultsPress Release – No. 8 / 2026 Zealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial results Copenhagen, Denmark and Boston, Massachusetts, April 30, 2026 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, announced that it will host a conference call on May 7, 2026, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the first quarter / first three months of 2026. Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; and Chief Medical Officer, David Kendall. The pre
- PRZealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight managementCompany announcement – No. 11 / 2026 Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management Phase 3 trials for chronic weight management planned for initiation in the second half of 2026Petrelintide demonstrated double-digit weight loss with placebo-like tolerability in the ZUPREME-1 Phase 2 trialZealand Pharma and Roche aim to unlock the full value potential of petrelintide providing a highly tolerable option for people living with overweight and obesity Copenhagen, Denmark, April 29, 2026 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced
- PRZealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trialCompany announcement – No. 10 / 2026 Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people living with obesity or overweight in Phase 3 trial In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a glucagon/GLP-1 receptor dual agonist1The trial met both weight loss primary endpoints and its key secondary endpoint evaluating waist circumference, a predictor of cardiometabolic risk, together demonstrating survodutide's potential to broadly improve metabolic health1In addition to
- PRTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsCompany announcement – No. 8 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, April 19, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, has received information on transactions in Zealand Pharma's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions. Please see the attached file(s). # # # About Zealand Pharm
- PRZealand Pharma launches long-term incentive programs for Zealand Pharma's Board of Directors, Corporate Management and employees for 2026Company announcement – No. 7 / 2026 Zealand Pharma launches long-term incentive programs for Zealand Pharma's Board of Directors, Corporate Management and employees for 2026 Copenhagen, Denmark, April 19, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces the implementation of long-term incentive programs for 2026 (the "LTIP") for the Board of Directors, Corporate Management and employees of Zealand Pharma, in accordance with the Company's remuneration policy and overall guidelines for incentive pay, as adopted at the annual general meeting held on March 20, 202
- PRZealand Pharma Appoints Eric Rojas as Vice President and Head of Investor RelationsPress release – No. 7 / 2026 Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations Bringing significant experience from Vertex Pharmaceuticals and Shire Copenhagen, Denmark and Boston, Massachusetts, April 14, 2026 - Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced the appointment of Eric Rojas, Vice President, Investor Relations, effective April 15, 2026. Eric will report to Henriette Wennicke, Chief Financial Officer, and will be based in Massachusetts, U.S. Eric brings more than two decades of experience in investor relations and finance, having supported both US
- PRTotal number of shares and voting rights in Zealand Pharma as of March 31, 2026Company announcement – No. 6 / 2026 Total number of shares and voting rights in Zealand Pharma as of March 31, 2026 Copenhagen, Denmark, March 31, 2026 – Zealand Pharma A/S ("Zealand Pharma" or "the Company") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month during which changes to its share capital have occurred. In Company Announcement No. 4 / 2026, dated March 19, 2026, Zealand Pharma announced a share capital increase due to the exercise of employee warrants. Fo
- PRResolutions from Zealand Pharma's Annual General Meeting 2026Company announcement – No. 5 / 2026 Resolutions from Zealand Pharma's Annual General Meeting 2026 Copenhagen, Denmark, March 26, 2026 - Zealand Pharma A/S ("Zealand Pharma" or the "Company") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today held its Annual General Meeting of 2026 as a partly electronic and partly physical general meeting (hybrid meeting). At the Annual General Meeting, all proposals presented to the Annual General Meeting were approved, save for the non-binding advisory vote on the remuneration report under item 7 on the agenda. Resolutions considered at the Annual General Meeting: Annual ReportThe Annual Genera
- PRZealand Pharma Establishes U.S. Research Hub in Cambridge, Massachusetts to Expand Drug Discovery Capabilities and Accelerate Medicine CreationPress release – No. 6 / 2026 Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachusetts to Expand Drug Discovery Capabilities and Accelerate Medicine Creation New research hub in Cambridge, Massachusetts, in the greater Boston area, expands global discovery capabilities, combining Zealand Pharma's more than 25 years of expertise in peptides and metabolic health with Boston's biotech innovation ecosystem. Copenhagen, Denmark and Boston, Massachusetts, March 24, 2026 - Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced the establishment of a new research hub in Cambridge, Massachusetts, in
- PRZealand Pharma increases its share capital as a result of the exercise of employee warrantsCompany announcement – No. 4 / 2026 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, March 19, 2026 – Zealand Pharma A/S ("Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 10,530 divided into 10,530 new shares with a nominal value of DKK 1 each. The capital increase is a consequence of the exercise of warrants granted under one of Zealand Pharma's employee warrant programs. Employee warrant programs are par
ZEAL FAQ
7 questionsWhat does Zealand Pharma A/S do?
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes Dasiglucagon single use syringe or autoinjector that has completed Phase III clinical trials for the treatment of severe hypoglycemia; Dasiglucagon dual-hormone artificial pancreas has...Where does ZEAL stock trade?
Zealand Pharma A/S (ZEAL) is listed on NASDAQ.What sector and industry is ZEAL in?
Zealand Pharma A/S operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Zealand Pharma A/S go public?
Zealand Pharma A/S (ZEAL) completed its IPO in 2017.What are analysts saying about ZEAL?
Zealand Pharma A/S has had 4 recent analyst actions on file. The most recent action was from Berenberg: Buy on 2024-03-05.What companies are similar to ZEAL?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ZEAL side-by-side with any of them on Quantisnow.How can I track ZEAL on Quantisnow?
Quantisnow aggregates Zealand Pharma A/S's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ZEAL to receive live email and push alerts on every new disclosure.